Articles
-
It’s Hard to Lower Drug Prices, If You Don’t Know What They Are
In an op-ed for The Hill, Professor Neeraj Sood writes that until legislators and regulators understand where the profits are flowing in the prescription drug distribution system, bills to control prices risk being ineffective.
Categorized in -
Losing Summer: 10 Months. Nearly 30 Visits to San Francisco’s Psychiatric ER. And a Suicide
Summer’s story reveals the weaknesses in San Francisco’s mental illness and addiction treatment system, according to a Center for Health Reporting-sponsored story.
Categorized in -
Young People Treated in Pediatric Emergency Departments Less Likely to Receive Opioids Compared to Similar Patients Treated in General EDs
Since the 1990s, children, adolescents, and young adults have also experienced dramatic increases in exposure to and harms from prescription opioids.
Categorized in -
CBO Estimate on Pelosi Drug Bill Misses its Long-Term Impact on Health
The CBO estimated that the Pelosi drug pricing reform legislation proposed would save Medicare $345 billion over seven years. It failed to look at the long-term effect on new drug discovery and the impact on population health.
Categorized in -
Accounting for Hope: Using ‘Mean Survival Gain’ to Price New Cancer Drugs
Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight. But there’s an important question that needs to be asked: What is the best metric to evaluate them?
Categorized in -
Retroactive Enrollment: A Feasible Way to Bring Auto-Enrollment to the Individual Market
Helping people benefit from the programs for which they are eligible could have a significant impact on the share of Americans with health coverage, possibly making the idea of automatic enrollment into coverage attractive across the political spectrum.
Categorized in -
Newly Approved Cancer Drugs Are Pricey, But Also Show Improved Longer-Term Survival Gains, According to New Study
Do the clinical gains offered by these drugs in treating specific cancer indications justify the price increases? Schaeffer Center researchers Alice Chen and Dana Goldman explore how we might measure the value of these drugs.
Categorized in -
Becerra Emphasizes Bold Solutions at USC-Brookings Schaeffer Initiative Event on Paths to Universal Coverage
In a panel discussion, Schaeffer experts outline policy approaches to improve the current healthcare system, following keynote remarks by California Attorney General Xavier Becerra.
Categorized in -
California Saw Reduction in Out-of-Network Care from Affected Specialties after 2017 Surprise Billing Law
This blog presents new evidence on observed changes in provider network breadth after the implementation of California’s 2017 law.
-
Most State Laws Aimed at Improving Drug Pricing Transparency Won’t Help, According to New Study
Less than 5 percent of state drug pricing laws passed between 2015 and 2018 will provide new information about pricing within the pharmaceutical distribution system.
Categorized in